Biosimilars Council — Leading on Biosimilars for America’s Patients
The Biosimilars Council, a division of the Association for Accessible Medicines, works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, […]
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1 Findings such as these, paired with high brand-name drug costs, are why commercial and employer-sponsored health plans have long looked forward to savings from biosimilar competition. Unfortunately, employers soon will be facing higher costs, if provisions in the Build […]
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines. According to recent data from IQVIA, savings from biosimilars increased over 800% from 2018 to 2020, from under $900M in 2018 to $7.9B in 20201. These savings are projected to reach over $30B annually by […]
Biosimilars Council Encourages Stakeholders, Advocates to Join #GlobalBiosimilarsWeek
WASHINGTON, D.C. (November 1, 2021) – AAM’s Biosimilars Council, in accordance with the International Generic and Biosimilar Medicines Association (IGBA), invites all biosimilars advocates and stakeholders to take part in the second annual Global Biosimilars Week on November 1st–5th. This social media awareness campaign will gather biosimilar resources, ideas, and stories from around the world […]
AAM and Biosimilars Council Statement on ACA Ruling in California v. Texas
WASHINGTON DC (June 17, 2021) – AAM and its Biosimilars Council welcome today’s decision by the U.S. Supreme Court in California v. Texas that ensures America’s patients and taxpayers can continue to benefit from biosimilar access and competition in the marketplace that is made possible by the Affordable Care Act’s inclusion of a biosimilar pathway. […]
Steven Selde Joins AAM’s Biosimilars Council as Director
WASHINGTON DC (May 24, 2021) – Today Steven Selde is joining the Association for Accessible Medicines (AAM) as Director of the Biosimilars Council. This division of AAM educates the public and patients about the safety and effectiveness of biosimilars, focusing on access, the regulatory environment, reimbursement and legal affairs. Member organizations include manufacturers and stakeholders […]
AAM Statement on IQVIA Report Examining Biosimilar Reimbursement and Adoption
WASHINGTON, D.C. (March 25, 2021) — U.S. patients rely on their health care providers to help them access biosimilars to treat their serious conditions. Today’s report reinforces the need and potential for straightforward policy proposals to encourage physicians in all settings of care to leverage biosimilar competition for their patients. We urge Congress and CMS […]
New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption
Since the first biosimilar launched in the U.S. market five years ago, the U.S. Food and Drug Administration (FDA) has approved 29 total biosimilars to treat diseases such as cancer and autoimmune conditions. Almost two-thirds of those products are commercially available to America’s patients. However, despite meaningfully lower prices, biosimilar adoption has trailed expectations, particularly […]
AAM Issue Brief: Biosimilars Medicare Part B
The Biosimilars Council Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Status in the Medicare Part B Program Despite the importance of biosimilars to reducing the cost of medicine, policymakers recently included a provision in a proposed bill that would have prohibited biosimilars from receiving pass-through status in Medicare Part B. While this provision was […]
2021 Generics and Biosimilars Outlook
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard. For most U.S. patients, affordable prescription medicines are just a short drive or walk from home to the drug store — or medicines are delivered right to their mailbox. This degree of convenience takes a lot of work […]
Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.
U.S. biosimilar medicines are 10 years old this year. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary: 10. Learn more about the […]
AAM Commends Introduction of the Increasing Access to Biosimilars Act
WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced […]
